BioNotebook: Trevena, MacroGenics, BioMarin, Kythera, Lpath, The Medicines Company/Alnylam
This article was originally published in Scrip
Executive Summary
Trevena registers initial public offering; MacroGenics prices IPO; BioMarin increases note sale; Kythera prices offering; Pfizer drops Lpath program; and The Medicines Company/Alnylam begin PCSK9 program.